ESMO World Congress on Gastrointestinal Cancer | Conference

Nivolumab Demonstrates Survival and Safety Benefit in Frontline HCC With Longer Follow-Up

July 1st 2020

Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from the long-term analysis of the CheckMate-459 trial in advanced hepatocellular carcinoma.

Dr. Sangro on Updated Findings From the CheckMate-459 Trial in Advanced HCC

July 1st 2020

Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.

Regorafenib Dose-Escalation Superior to Standard Dosing in mCRC

June 22nd 2018

Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.

TAS-102 Benefit Consistent in Real-World Study for mCRC

June 22nd 2018

TAS-102 (trifluridine/tipiracil; Lonsurf) continued to show consistent benefits and safety in a real-world treatment setting for patients with refractory metastatic colorectal cancer.

O'Reilly Discusses Status of Immunotherapy Research in Pancreas Cancer

June 22nd 2018

Eileen M. O’Reilly, MD, speaks to the progress being made with immune therapies in pancreatic cancer.

Dr. O'Reilly on Immunotherapy in Pancreatic Cancer

June 22nd 2018

Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in the treatment of patients with pancreatic cancer.

Dr. Finn Recaps Second-Line Advancements in HCC

June 22nd 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, recaps recent second-line advancements in hepatocellular carcinoma.

Atezolizumab Combo Not Superior to Regorafenib for mCRC

June 22nd 2018

Atezolizumab alone or in combination with cobimetinib failed to show superior overall survival compared with regorafenib for patients with chemorefractory metastatic colorectal cancer.

TAS-102 Prolongs Survival in Phase III Gastric Cancer Study

June 21st 2018

TAS-102 (trifluridine/tipiracil; Lonsurf) provided a 31% reduction in the risk of death compared with placebo in patients with heavily pretreated metastatic or advanced gastric cancer.

Pembrolizumab Fails to Show Survival Benefit in PD-L1 ≥1 Gastric/GEJ Cancers

June 21st 2018

Second-line treatment with pembrolizumab (Keytruda) did not significantly improve overall survival or progression-free survival in patients with advanced or metastatic gastric or gastroesophageal junction cancer with a PD-L1 combined positive score ≥1.

Dr. Kim on PRODIGE 37 in Pancreatic Cancer

June 21st 2018

George P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.

Dr. Demetri on Larotrectinib in TRK-Fusion GI Cancers

June 21st 2018

George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, senior vice president, Experimental Therapeutics, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses the use of larotrectinib in patients with TRK-fusion gastrointestinal (GI) cancers.

Conroy Highlights Practice-Changing Findings With Chemo Combo in Pancreatic Cancer

June 21st 2018

Thierry Conroy, MD, discusses the PRODIGE 24/CCTG PA.6 trial and shares his insight on future research with this treatment regimen.

TAS-120 Shows Promise in Cholangiocarcinoma

June 21st 2018

TAS-120 demonstrated a clinically meaningful benefit with a manageable toxicity profile in patients with cholangiocarcinoma harboring FGFR2 gene fusions, including patients who had progressed on an FGFR inhibitor.

Adding SIRT Does Not Provide Survival Benefit in Advanced HCC, Except in Select Patients

June 20th 2018

Selective internal radiation therapy in combination with sorafenib (Nexavar) did not provide a significant survival improvement compared with sorafenib alone in patients with advanced hepatocellular carcinoma.

Ramucirumab Extends Survival for AFP-Elevated HCC in Pooled Analysis

June 20th 2018

Treatment with second-line ramucirumab improved median overall survival by 3.1 months compared with placebo in patients with advanced hepatocellular carcinoma with alpha-fetoprotein levels ≥400 ng/ml.

Dr. Conroy Discusses Survival Data With FOLFIRINOX in Pancreatic Cancer

June 20th 2018

Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses survival data with modified FOLFIRINOX in pancreatic cancer.

Dr. Finn Discusses the Pooled Analysis of REACH and REACH-2 in HCC

June 20th 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the pooled analysis of the REACH and REACH-2 studies in patients with hepatocellular carcinoma.

Dr. O'Reilly on Immunotherapy in Pancreatic Cancer

January 8th 2018

Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in patients with pancreatic cancer.

Dr. Modest on Study of Surgical Intervention in CRC

July 6th 2017

Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer.

NEXT PAGE
PREVIOUS PAGE